Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
•
Medical Oncology
How would you approach new dermal mets in a patient who recently finished chemoradiation for head and neck SCC?
Answer from: Radiation Oncologist at Academic Institution
Dermal mets are M1 disease. Since the patient received chemo, (s)he has a medical oncologist who should manage the case moving forward.
Sign In
or
Register
to read more
Answer from: Radiation Oncologist at Academic Institution
Palliative systemic therapy or supportive care.
Sign In
or
Register
to read more
18773
18774
Related Questions
What are your top takeaways in Head & Neck Cancers from ASCO 2025?
How would you approach post-op radiation recommendations in patients who had neoadjuvant chemoimmunotherapy for HPV mediated OPSCC s/p TORS who have a complete pathologic response (pCR)?
How would you manage the side effects/toxicities (e.g., pain, swelling, erythema) of adjuvant EBRT to the ear for cutaneous SCC?
For unresectable-appearing BRAF V600E papillary thyroid cancer involving the trachea and carotid artery, is neoadjuvant targeted therapy a viable path to surgery, or is definitive radiation the better option?
Is there a scenario in which you would consider observation for T4a SCC involving the mandible?
What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?
How do you approach cisplatin dosing for locally advanced head and neck SCC in HPV-positive and HPV-negative patients?
What is your recommendation for patients who are on weight loss medications like GLP-1-based therapies while receiving chemoradiation for head and neck cancer?
In p16-positive oropharyngeal squamous cell carcinoma, when induction therapy is considered before definitive chemoradiation, how do you choose between a traditional TPF regimen and carboplatin/paclitaxel/pembrolizumab?
How do you counsel patients regarding alcohol consumption following treatment of head and neck cancer?